This patient harbored pathogenic mutations in NRAS, CCND1, and ATM. Activated MAPK pathway by NRASGln61Lys could potentially rescue MCL cells from BTKi and increase MCL pathogenicity. This evidence concerns the gene NRAS and mantle cell lymphoma.